‹ Browse★ Saved
📱 Tech & Apps
Iovance Biotherapeutics
(IOVA ↗)
iovance.com ↗
Iovance sells *Amtagvi* — the first FDA-approved one-time T-cell therapy for a solid tumor (advanced melanoma). Revenue is real. So is the loss column. The question is whether the manufacturing engine can keep scaling while the company expands lifileucel into more cancers.
Updated · Q1 2026 · May 2026
6
Chapters
~18
Min read
~$285M / yr revenue · ~975 employees · public since 2014
🌶️🌶️🌶️🌶️
Spice: Ghost (5/5)
More filled = spicier (more aggressive), not "better." Tap a row to see what it means.
What is spice?
Your progress
0 of 6
1
Growth
~3 min
Amtagvi Is Real Revenue
Revenue grew *45%*. Management *raised* full-year guidance to $350-370M.
›
2
Financial Health
~3 min
Cash Through 2028
*$319M* of cash, projected to fund operations *well into 2028.* The math depends on burn going down — which it just did.
›
3
Moat
~4 min
The Manufacturing Moat
TIL therapy isn't a pill — it's a *32-day manufacturing process* using each patient's own cells. That difficulty *is* the moat.
›
4
Management
~3 min
An Interim CEO at the Inflection
Frederick Vogt is the *interim* CEO. Iovance is publicly recruiting a permanent one — at the most important moment in its history.
›
5
Behind the Numbers
~2 min
The Story Behind the Numbers
A 45% growth quarter, four new clinical readouts, and a UK setback — all in one release.
›
6
Risk
~3 min
The One-Product Risk
*One drug,* *one factory,* *one CEO search.* That's the shape of the risk.
↻ Next update · Aug 7
est. Aug 7, 2026 · Q2 2026 · Iovance IR ↗
›
✦ Reader takes on Iovance Biotherapeutics
0 comments
Drop your read. See how others are calling this brief.
No one's weighed in yet. Be the first.
↗ Share Iovance Biotherapeutics
↻ The read keeps updating
You're reading the 6 opening chapters. After that, every time Iovance files a new report, the chapters get updated here.